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Abstract
Endocrine signaling via nuclear receptors (NRs) is known to play an important role in normal
physiology as well as in human tumor progression. Hormones regulate gene expression by
altering local chromatin structure and, thereby, accessibility of transcriptional co-regulators to
DNA. Recently it has been shown that non-histone proteins involved in hormone signaling,
such as nuclear receptors and NR co-activators, are regulated by acetylation, resulting in
their altered transcriptional activity. NAD-dependent protein deacetylases, the sirtuins (Sir2related enzymes), directly modify NRs. Because sirtuins have been shown to regulate tumor
cellular growth, aging, metabolic signaling and endocrine hormone signaling, they might play
a role in cancer progression. This review focuses on the role of acetylation and the sirtuins in
nuclear hormone receptor signaling.

Introduction
Histone modification
In eukaryotes, genomic DNA is packaged by histones and non-histone proteins into
chromatin, which is further organized as repeating units of nucleosomes. The nucleosome
consists of 147 base pairs of DNA wrapped around a protein core of histones (an H3–H4
tetramer and two H2A–H2b dimers) [5]. Histone proteins consist of a globular domain and a
more flexible charged N-terminus, known as the histone tail. Covalent modifications of the
histone tail include acetylation, phosphorylation, methylation and ubiquitination. Such
modification of chromatin structure is evident during cell-cycle progression, DNA replication,
DNA damage and repair, recombination and overall chromosome stability [5].In addition,

alteration to histones and non-histone proteins by acetylation plays a role in transcriptional
activation and DNA-binding affinity, protein stability, protein–protein interactions, protein
transport within the cell and nucleus, and activity of molecular chaperone proteins [6].
The acetylation status of histone proteins alters gene transcription. Removal of acetyl groups
from lysine residues results in compaction of chromatin and, hence, repression of gene
transcription [6]. As such, transcriptionally active euchromatin is typically hyperacetylated,
compared with inactive heterochromatin which tends to be hypoacetylated [7].Inaddition, the
N-terminal modification of histone tails provides recognition sites for factors involved in gene
transcription. Acetylation of lysine residues provides a recognition motif for bromodomains.
Other post-translational modifications of histones serve to recruit additional proteins with
enzymatic activity and/or tethering functions for other proteins: methylation is recognized by
chromo-like domains of the Royal family and phosphorylation is recognized by 14–3-3
proteins. Methylated histones (e.g. H3K4-Me3) recognize the PDH domain contained within
BPTF, which recruits the NURF complex.
Post-translational modification of histones, in turn, can modify subsequent access of other
enzymes. Distinct modifications of lysines are mutually exclusive. Binding of proteins might
be excluded or enhanced by such modifications, and a catalytic activity of an enzyme can be
modified by local enzymatic changes. For example, the phosphorylation of H3S10 regulates
the binding of HP1 to methylated H3K9. Furthermore, isomerization of H3P38 governs
methylation of H3K36 by Set 2. The prevailing evidence suggests that signal transduction
pathways might coordinate sequential and carefully orchestrated post-translational
modification of histones with distinct enzymatic activity. Although historically the notion of a
histone code was used to describe the role of modifications in governing DNA functions, an
expanded view considers the post-translational modification of histones to encode precise
information governing gene expression. The hypothesis of the ‘histone code’ was initially
proposed to be responsible for extending the information potential of genetic material within a
cell [5].
Multiple proteins with acetyl transferase activity have been identified, and they are most
commonly referred to as histone acetyl transferases (HATs). HATs are classified on the
basis of their subcellular location: type A HATs are usually localized in the nucleus, whereas
type B can be found in the cytoplasm. Type A HATs are involved in transcriptional regulation
through their acetylation of nucleosomal histones within local chromatin. However, within the
cytoplasm, type B HATs are thought to possess a ‘house-keeping’ role, acetylating newly
formed free histones. Alterations in expression, translocation, amplification or mutationof
genes encodingHATshave been found in several cancers [6]. One example is the breastcancer susceptibilitygene BRCA2,which exhibits acetyltransferase activity [8].
The histone deacetylases (HDACs) have been divided into four groups based on their
similarity to yeast transcriptional repressors. Class I and II HDACs are similar to the yeast
Rpd3p and Hda1p proteins. Class III HDACs share similarity to the yeast transcriptional
repressor Sir2p and are referred to as sirtuins. Class I and II HDACs are characterized by
their sensitivity to inhibition by trichostatin A (TSA), whereas class III HDACs are nicotinamide
adenine dinucleotide (NAD)-dependent. A fourth class includes the deacetylase HDAC11 [9].
This review will concentrate on the class III HDACs, the sirtuins.
Nuclear receptor modification by acetylation

Since the identification of p53 as a non-histone target of HATs, a growing body of evidence
has shown an important role for acetylation and deacetylation of non-histone proteins in
cellular physiology [10]. Several transcription factors, including the nuclear hormone
receptors (estrogen receptor α (ERα), androgen receptor (AR), thyroid hormone receptor β
(TRβ) and glucocorticoid receptor (GR)), p53 [11,12], GATA-1 [13], GATA-2 [14], GATA-3
[15], EKLF [16] and HMG proteins [17], are altered by acetylation. Acetylation of transcription
factors results in altered binding to DNA, transcriptional activation, protein stability,
subcellular localization and altered protein–protein interactions. For example, the tumor
suppressor p53 is acetylated by p300, which functions as a rate-limiting cointegrator in
diverse nuclear receptor signaling pathways, within its C-terminal domain, resulting in
sequence-specific DNA binding [11] both in vitro and in vivo [12]. Recent studies have
demonstrated that the individual acetylation sites of p53 determine its DNA binding [18].
Differential acetylation at distinct acetylation sites results in altered downstream effects,
including cell survival after DNA damage, interaction with co-repressors and co-activators,
interaction with downstream promoters, nuclear retention and DNA binding.
The AR plays a crucial role in prostate cancer proliferation as androgens induce proliferation
and inhibit apoptosis. Androgen ablation therapy remains an important therapeutic in the
management of metastatic prostate cancer. Hyperactivity of the AR is associated with loss of
responsiveness to androgen therapy and androgen-insensitive prostate cancer (AIPC). Posttranslational modification of the AR, including hyperacetylation, probably contributes to this
hyperactivation. Acetylation of the AR by HATs (e.g. CBP and p300) regulates ligand binding
and alters the affinity of the AR for co-regulators. Acetylation of the AR might thereby regulate
prostate cancer growth and cell death [19].
The AR was the first nuclear receptor that was shown to be directly acetylated [20]. The
residues of the AR that are acetylated in vitro by p300 are conserved among species and with
other nuclear receptors [21]. Point mutation of the AR acetylation site to create acetylation
mimic mutants enhanced ligand-dependent transactivation [20]. By contrast, acetylation dead
mutants of the AR abrogated ligand-dependent transactivation. Although several functions
are regulated by acetylation, including transactivation and contact-independent growth, the
transrepression cAMP-and Akt-regulated function of the AR remained unaffected [22].
In vivo, acetylation of the AR is enhanced by agonists such as bombesin and its ligand
dihydrotestosterone [23]. The physiological function of the acetylation site of the androgen
receptor includes regulation of cellular growth [24].The introduction of AR acetylation mimic
mutants into human prostate cancer cells promoted the growth of cells both in vitro and in
vivo. This enhanced cellular growth was a function of both enhanced cellular proliferation and
reduced cellular apoptosis. This finding was of importance because it was the first study to
demonstrate that acetylation of a transcription factor directly regulated contact-independent
growth. The molecular mechanisms and genetic targets regulating the cell survival and
proliferation phenotype remain to be characterized completely.
It was previously shown that the AR can induce apoptosis. Substitution mutations of the AR
acetylation sites abrogated tumor necrosis factor-α (TNF-α) and trail-induced apoptosis of
human prostate cancer cells in culture. AR activity is induced by mitogen-activated protein
kinase (MAPK) kinase kinase, which induces MKK4, Jun N-terminal kinase (JNK) and IκB
kinases. MEKK1 induces prostate cancer cell apoptosis in an AR-dependent manner through
JNK. Co-expression of MEKK1 and the wildtype AR in the presence of dihydrotestosterone

induced apoptosis. Mutation of the AR acetylation site abrogated MEKK1-induced apoptosis.
Collectively, these studies demonstrate that MEKK1 (Jun-kinase kinase)-dependent cellular
apoptosis involves the AR acetylation site. In addition, AR acetylation site mimic mutants
were resistant to MEKK1-dependent apoptosis [25].
Prostate cancer cells transduced with acetylation mimic mutants of the AR showed enhanced
cellular proliferation and induction of Ki67 [24]. These cells exhibited increased expression of
proliferative cell-cycle markers including cyclin D1. Chromatin immunoprecipitation assays
demonstrated enhanced recruitment of the gain-of-function AR acetylation site mutants to the
cyclin D1 promoter [24]. Biochemical analysis of the molecular mechanisms by which the AR
acetylation site regulates gene transcription indicated that lysines 630, 632 and 633 play a
key role in the recruitment of the co-activator protein p300 and the disengagement of corepressor complexes including NCoR, HDAC1 and Smad3 [25]. In vitro analysis
demonstrated the importance of these lysine residues in serving as docking sites for p300
[25,26] (Figure1).
Signaling cascades in transcription factors
Studies of histones have demonstrated the interplay among post-translational modifications.
For example prior modification of histones by phosphorylation regulates subsequent
acetylation. The identification of post-translational modification of transcription factors raised
the possibility that, like histones, one post-translational modification (i.e. phosphorylation) of
transcription factors might regulate subsequent modification (i.e. acetylation or methylation).
This hypothesis indicates that sequential post-translational modifications of transcription
factors by phosphorylation, acetylation and ubiquitination might determine the signaling
specificity of a transcription factor. The model in which these sequential post-translational
modifications occur within transcription factors has been called signaling cascades in
transcription factors (SCITs).
Consistent with this model, the AR is modified by both acetylation and phosphorylation, and
AR acetylation affects phosphorylation-dependent signaling. MAPK pathways activate the
AR, and the AR is phosphorylated by several distinct signaling cascades. In view of previous
studies suggesting that H3 phosphorylation and acetylation might be linked events [27], we
investigated the role of the AR acetylation site in signaling by the key kinases implicated in
AR signaling, MAPK, Akt and protein kinase A (PKA). Mutation of the AR acetylation site did
not affect MAPK signaling [22]. The AR acetylation site mutants were, however, defective in
regulation by HDAC inhibitors, Akt signaling and cAMP signaling. cAMP signaling normally
regulates recruitment of the AR to an androgen response element in chromatin
immunoprecipitation assays; however, this recruitment was abolished by AR acetylation site
mutation [22]. Furthermore, the AR normally forms three molecular weight forms dependent
upon phosphorylation. Mutation of the AR acetylation site abrogated formation of the 114kDa
phosphorylated form. The cAMP pathway, once activated, results in rapid dephosphorylation
of the AR, in part through the induction of PKA-induced phosphatases. Collectively, this
analysis of the inter-relationship between phosphorylation and acetylation of the AR has
shown that AR acetylation regulates cAMP and Akt, but not MAPK-dependent,signaling of the
AR [22](Figure2).These studies are consistent with prior analysis in which MAPK signaling to
the ERa was unaffected by mutations in the ERa acetylation site [21].
Chromatin access of the nuclear receptors (NRs) is regulated by the acetylation of local

histones and histone demethylases. Point mutation of the six distinct AR phosphorylation
sites led to the identification of a single site capable of regulating HDAC responsiveness [22].
Chromatin immunoprecipitation assays demonstrated enhanced AR recruitment in the
context of local chromatin, upon addition of HDAC inhibitors, or through treatment with DHT.
Acetylation dead AR mutants were defective in both ligand- and HDAC-dependent
recruitment to the endogenous PSA promoter [22]. These studies suggest that the acetylation
status of the nuclear receptor itself regulates access to local chromatin. The model in which
local enzymatic activity of HDACs regulates AR occupancy is consistent with a growing body
of evidence that multiple distinct nuclear receptor modifying enzymes co-occupy AR-binding
sites in the context of local chromatin (Figure 3). For example, histone demethylases have
been shown to co-occupy nuclear hormone receptor sites, performing a gatekeeper function
of preventing the occupancy of unliganded nuclear receptors into the context of local
chromatin [28]. Many studies have dissected the components of the AR co-repressor and coactivator complexes (reviewed in Ref. [29]).
In addition to the AR, it has been demonstrated that several other nuclear receptors are
acetylated. The ERa was initially shown to be acetylated by p300 at the same motif as the AR
[21]. Mutational analysis identified a minimal region sufficient for acetylation and an ERα
peptide encoding the site served as substrate for p300 HAT activity with similar properties to
H3. Proteomic analysis demonstrated that Lys302 and Lys303 are preferential sites for
acetylation. Independent clinical study identified Lys K303 as a site of frequent mutation in
breast cancer [30]. Like p53, in which multiple distinct acetylation sites have been identified
[18], additional acetylated ERα Lys residues were identified recently (K266/2681) in assays
combining SRC1 with p300.
The regulation of glucocorticoid receptor activity by acetylation is complex. HDAC6 regulates
HSP90-dependent GR maturation [31]. The GR is acetylated after ligand binding.
Mutagenesis of the acetylated residues (K494/ 495) reduced GR acetylation and GRmediated repression of nuclear factor-kB (NFkB) activity [32]. The addition of thyroxine
results in the accumulation of acetylated TRb within 30 to 45 min. Inhibition of MAPK activity
reduced thyroxine-induced TRb acetylation [33].
In addition to the nuclear receptors and histones, several other components of the nuclear
receptor signaling cascades are substrates for acetylation. For example, kinases (MEK2 and
IKKa) and nuclear receptor co-regulators (p300, MTA1, PGC1a ACTR, and HDACs) also
serve as substrates for acetylation by HATs. Collectively, these studies indicate an important
link between the acetylation of non-histone proteins and nuclear hormone receptor signaling
(Figure 3).
Sirtuins: Sirt1 and the nuclear sirtuins
+

The sirtuin family is a group of nicotinamide (NAD )-dependent deacetylases that are
conserved from archaeobacteria to eukaryotes [4,34]. The sirtuins were originally classified
as type III HDACs, because histones were the first identified substrates of the yeast Sir2p
+

gene [35]. Sir2 conveys NAD -dependent ADP-ribosyltransferase activity, that is, the
+

enzymatic activity of sirtuins is regulated by NAD . In mammals, there are seven homologues
of the yeast Sir2 gene, SIRT1–SIRT7, each with significant diver sity in function (Table 1).

Mammalian sirtuins can be localized to the nucleus, cytoplasm or mitochondria, with distinct
substrates and a broad range of functions [2]. The structure of the sirtuins includes a
conserved core domain, with all seven homologues differing in their N-or C- terminal
sequences [35]. SIRT1 is the human homolog of the yeast silent information regulator 2 (Sir2)
gene. Endogenous levels of nicotinamide probably limit Sirt1 activity, while the mechanisms
+

regulating Sir2 activity might be regulated by either altered ratios of cellular NAD :NADH [36]
+

or free nicotinamide, and free NAD levels might suppress Sir2 activity [37].
The three nuclear sirtuins (SIRT1, SIRT6, and SIRT7) have distinct functions. SIRT1 is
known to deacetylate more than ten substrates, including the nuclear receptors (AR, ERα),
the NR co-activators (PGC1α, p300) [38–40], Ku70 and several transcription factors that are
regulated by p300 (NFκB, FKHR). SIRT6 has weak deacetylase activity but significant autoADP-ribosyltransferase activity. In an outbred background, SIRT6-/- mice develop defective
skeletal fusion, osteoporosis, low insulin-like growth factor1 (IGF-1) levels, and hypoglycemia.
Genomic instability in these mice is associated with enhanced sensitivity to DNA damaging
agents and defective base excision repair. SIRT7 exhibits a nucleolar distribution within
+

proliferating, but not quiescent, cells. This sirtuin lacks NAD -dependent deacetylase activity
+

and interacts with RNA polymerase I. An NAD -binding motif in SIRT7 indicates that this
+
family member might function to sense NAD concentrations in proliferating cells and thereby
regulates RNA Pol I activity.
Cytosolic SIRT2 binds and deacetylates α-tubulin and histones, while preferentially
deacetylating H4K16 [41]. Expression of SIRT2 is reduced in some cancers [42] and is
increased during mitosis co-localizing with chromatin during the G2M phase [43]. SIRT2
deacetylation of cytoskeletal proteins might regulate migration and/or their intracellular cargo
in response to altered intracellular metabolism.
The extended sirtuin family
The mitochondrial sirtuins (SIRT3, SIRT4 and SIRT5) appear to regulate mitochondrial
respiratory function. Both SIRT3 and SIRT4 are imported into the mitochondrial matrix
[44,45]. SIRT3 is required for expression of the uncoupling protein 1 (UCP-1) [46]. SIRT3
deacetylates and activates acetyl-coenzyme-A synthetase (AceSC2) [44, 47], thereby
facilitating the entry of acetate into the tricarboxylic acid (TCA) cycle. Polymorphisms of
SIRT3 have been linked to longevity [48,49]. SIRT4 ADP-ribosylates mitochondrial glutamate
dehydrogenase, and subsequently inhibits its activity and blocks the conversion of glutamate
to α -ketoglutarate. The cellular interactions and biological significance of SIRT5 are not yet
known, although its structure suggests a deacetylase function.
Sirtuins and nuclear receptors
In addition to the TSA-sensitive histone deacetylases, NAD-dependent histone deacetylases
(the sirtuins) regulate histone and non-histone protein structure and function and are
important for nuclear hormone receptor signaling. One non-histone protein that is
+

deacetylated by a sirtuin, Sirt1, is the co-activator p300 [39]. Sirt1 represses p300 in a NAD dependent manner. The p300 HAT contains multiple distinct domains, including the cell cycle
regulatory domain (CRD1), and lysine residues within the CRD1 domain are required for Sirt1

repression of p300. The Lys residues within p300 function as substrates for Sirt1-mediated
deacetylation, as well as for sumoylation. Additionally, the SUMO-specific protease, SSP3,
antagonizes Sirt1-mediated repression of p300 [39]. Collectively, these studies demonstrate a
key role for Sirt1 in regulating p300 deacetylation. Sirt1 regulation of p300 might thereby
integrate metabolic signals within the cell, because diverse nuclear receptors are regulated
by p300.
In view of the key role for the AR acetylation site in regulating prostate tumor cellular growth
in vivo, together with evidence that the incidence of prostate cancer increases with aging and
the finding that the sirtuins might play a role in organismal aging, the potential role of the
sirtuins in regulating AR function has been investigated. The AR has been shown to be
repressed by SIRT1 in prostate epithelial cells. Consistent with this, confocal microscopy
revealed co-localization of the AR and SIRT1 in a nuclear subcompartment [38]. SIRT1
inhibited cellular proliferation in AR-expressing prostate cancer cell lines but not in cells that
do not express AR [38], demonstrating that their interaction is physiologically relevant.
Inhibition of SIRT1 with antagonists increased androgen-regulated gene transcription.
Importantly, inhibitors of endogenous Sirt1 (Sirtinol, splitomycin and nicotinamide) induced
endogenous AR gene expression. The repression of AR activity by Sirt1 required the catalytic
function of Sirt1. The AR lysine residues that are acetylatedbyp300 serve as substrates for
Sirt1-mediated deacetylation (Figure3). The ability of SIRT1 to deacetylate the AR and
repress its activity might provide a novel and effective cancer therapy.
What might be the physiological significance of the finding that Sirt1 inhibits AR activity? This
model is consistent with a known role of androgens in maintaining muscle mass and in the
induction of genes associated with muscle development. The AR is known to play a key role
in several biological functions. In addition to maintaining muscle mass and reducing fat mass,
the AR governs the pathological state driving tumors and the progression of prostate cancer.
+

The metabolic changes induced by pyruvate increase the NAD :NADH ratio in muscle cells
thereby inhibiting muscle gene expression. Conversely the induction of lactate, which would
+

reduce NAD , might stimulate muscle gene expression [50].
In the case of prostate cancer, recent studies have demonstrated that global changes in
histone acetylation occur, in particular acetylation of H3K18, H4K12 and H3K9 [51]. These
changes in acetylation are thought to be predictive of prostate cancer recurrence [51]. The
role of Sirt1 in altering histone acetylation during prostate cancer progression and/or through
AR function is currently unknown. However, it is known that during prostate cancer
progression, cells shift towards cytosolic glycolysis [52]. The induction of lactate that occurs
during prostate cancer progression [53] might be anticipated to inhibit Sirt1 and thereby
enhance AR function [38].In prostate cancer cells, Sirtinol, a noncompetitive inhibitor of Sirt1,
induced expression of the endogenous AR gene, as did the selective chemical Sirt1 inhibitor,
splitomycin [38]. Therefore, it is proposed that Sirt1 might inhibit prostate cancer cellular
growth by inhibiting AR function.
Subsequent studies have demonstrated that other nuclear receptors, including the ERα, TRβ
and GR, contain a functional conserved acetylation motif. The role of sirtuins in regulating
these receptors is not known at this time; however, there is indirect evidence for the
regulation of ERα by sirtuins. The ERα is acetylated by p300 at lysine residues within its
hinge and ligand-binding domains [54]. These lysine residues are well conserved between

species and with other nuclear receptors. Resveratrol was thought to function as a specific
SIRT1 activator [55] and is an agonist for the ER [56]. However, resveratrol has diverse
biological effects [57], including antioxidant properties, inhibition of mitochondrial ATPases
and competition with co-enzyme Q, and this has led to the substrate specificity of resveratrol
being called into question. Resveratrol was shown to enhance binding and deacetylation of
peptide substrates that contain fluorophore (Fluor de Lys), a non-physiological fluorescent
moeity, but not a similar acetylated peptide without a fluorophore. Resveratrol did not exert
detectable effects on Sir2 activity (transcriptional silencing near telomeres, rDNA silencing)
[58,59].
Resveratrol has chemopreventative properties [60], such as inhibiting preneoplastic
mammary gland lesions [60]. The role of resveratrol in breast cancer cellular proliferation
remains controversial [61,62].Inthe estrogen-dependent breast cancer cell line T47D,
resveratrol promoted cell proliferation [56], whereas Mgbonyebi et al. [63] showed an antiproliferative effect of resveratrol in both ER-positive and ER-negative breast cancer cells. It
has been reported that resveratrol has estrogenic and anti-estrogenic properties. A prevailing
view is that resveratrol is a selective estrogen receptor modulator (SERM) that functions as
an ER agonist in some tissues and as an ER antagonist in others. Further clarificationis
necessary to determine whether resveratrol functions through SIRT to regulate ERα activity
and whether this agent will have a clinical benefit in women diagnosed with breast cancer.
Sirtuins and metabolism
The sirtuin-dependent regulation of nuclear receptor coactivators has been linked to the
regulation of glucose metabolism. Calorie restriction promotes insulin sensitivity and
subsequent reductions in blood glucose and insulin levels [64]. Recent studies have linked
Sirt1 to the nuclear receptor co-regulator PGC1a. SIRT1 regulates hepatic gluconeogenesis
by promoting increased gluconeogenesis and by repressing glycolytic gene function. Through
deacetylation of PGC1-a, SIRT1 enhances gluconeogenic gene transcription via interactions
with hepatocyte nuclear factor 4a [40] associated with repression of glycolytic genes. SIRT1
regulation of FOXO1 activity in hepatocytes has also been shown to enhance
gluconeogenesis and glucose release [65].In addition, SIRT1 regulates insulin secretion in
pancreatic b-cells [66,67]. These two groups have demonstrated that this mechanism is
dependent on SIRT1-mediated repression of the uncoupling protein 2(UCP2) gene.
A growing body of evidence has suggested a role for estrogen and estradiol-dependent gene
transcription in regulating double-stranded DNA break repair [68].In this regard addition of
estradiol induces transient double-stranded DNA breaks to which procyclic acidic repetitive
protein (PARP) is recruited. Recent findings suggest a role for sirtuins in double-stranded
DNA break repair. SIRT6 is predominantly a nuclear protein, with high levels of expression in
mouse muscle, brain and heart [69]. Recent evidence points to a role for SIRT6 in resistance
to DNA damage and suppression of genomic instability [70]. SIRT6-/- mice die within four
weeks of birth after developing abnormalities that include loss of subcutaneous fat,
lordokyphosis and severe metabolic defects [70]. Furthermore, MEFs deficient in SIRT6 show
impaired proliferation and increased sensitivity to DNA damaging agents [70]. Haigis and
Guarente [2] propose that SIRT6 can ADP-ribosylate substrate proteins involved in the base
excision repair pathway, a mechanism by which SIRT6 could be regulating DNA damage
repair [70].

At this time the role of nuclear receptors in aging and their relationship to the function of
sirtuins in aging is unknown. Restriction of calorie intake extends lifespan in several
organisms, including yeast, flies, spiders, worms and rodents [2]. On the basis of the
observation that Sir2 extension of lifespan in Caenorhabditis elegans involves the forkhead
protein, Dauer formation 16 (DAF-16), a model has been proposed in which caloric restriction
prolongs life through Sir2 signaling in conjunction with the DAF-2 insulin-like signaling
pathway. SIRT1 expression is induced by calorie restriction and fasting, suggesting a role for
SIRT1 in the regulation of fasting responses. Increased dosages of Sir2 homologues are also
capable of increasing lifespan [71]. It has been proposed that Sir2 promotes longevity in
yeast cells by reducing recombination of rDNA (rDNA) and the subsequent formation of
extrachromosomal rDNA circles (ERCs). Strains deficient in SIR2 and NPT1 do not show an
+

extension in lifespan [72], thereby emphasizing the importance of NAD -activated Sir2p in
prolonging life.
Conclusion
At least eight distinct types of post-translational modification of histones have been described.
Several of the enzymes responsible for these modifications directly modify nuclear receptors.
Acetylation, like phosphorylation, is now known to govern cellular growth [24]. The addition of
ligand to nuclear receptors induces receptor acetylation [23]. Nuclear receptors contain intrareceptor signaling modules consisting of cascades of phosphorylation, acetylation,
ubiquitination and perhaps sumoylation [73]. Histone-modifying enzymes, including histone
acetylases and arginine methyltransferases, co-associate with most nuclear receptors in the
context of local chromatin [28]. The finding that sirtuins directly regulate nuclear hormone
receptors provides a new mechanism by which nuclear receptors might coordinate metabolic
+

signaling. Local metabolic changes in NAD ;NADH ratios sensed by the sirtuins might, in
turn, regulate local activity of nuclear receptors. As nuclear receptors are located in distinct
subcellular compartments, including the cellular membrane, mitochondria, cytoplasm and
nucleus, and distinct sirtuins occupy discrete subcellular compartments, it will be of interest to
determine the role of the sirtuins on nuclear receptor activity in these distinct subcellular
locales. The finding that SIRT1 regulates the nuclear receptor co-integrator p300 provides a
+

new mechanism by which local NAD :NADH changes might coordinate nuclear receptor
function within the cell.
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Figures and Tables

Figure 1
+

Domain architecture of human sirtuin family of Class III NAD -dependent histone
deacetylases Schematics represent the domain structure of human sirtuins. Amino acid
positions are noted above each schematic. The domains are represented in different colors.
SIRT1 is not drawn to the same scale as the other sirtuins. Adapted from UniProt Universal
Protein Resource Database.

This article is a post print. It is the authors’ final version prior to publication in Trends in Endocrinology and Metabolism 18(9):356-364,
2007. Published version available at DOI 10.1016/j.tem.2007.07.007. Copyright © 2007 by Elsevier Ltd.

Figure 2
Proteins involved in ligand-induced hormone signaling are acetylated nuclear receptor
ligands that induce multiple downstream molecular interactions. Proteins known to be
involved in nuclear receptor signaling are shown. Proteins with an asterisk have been shown
to serve as substrates for acetylation in vitro both within the cytosol and in the nucleus.

Figure 3
Transcriptional regulation of the androgen receptor through epigenetic modifications.
Acetylation and subsequent activation of the androgen receptor is mediated by p300 and
P/CAF at the indicated Lys residues. The AR is also capable of being methylated by CARM1
and phosphorylated by MAPK, PKC or PKA at multiple serine residues. The exact location of
such residues remains a controversial area of research. Because these modifications are
mutually exclusive, but can occur on the same residues, the possibility of ‘crosstalk’ between
modifications is suggested. Deacetylation and, therefore, transcriptional repression is elicited
by SIRT1. Also shown within the figure insert is the interaction between histone
acetyltransferases P/CAF and p300 as they associate with H4K16.

Table 1
a

The functions, interactions and subcellular location of the mammalian sirtuins
a

Adapted from Refs [35, 74].

